Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
genentech
14
×
life sciences
national blog main
biotech
national top stories
boston blog main
boston top stories
san francisco blog main
san francisco top stories
national
new york blog main
new york top stories
fda
indiana blog main
indiana top stories
san diego blog main
san diego top stories
boulder/denver blog main
boulder/denver top stories
cancer
detroit blog main
detroit top stories
eli lilly
raleigh-durham blog main
raleigh-durham top stories
roche
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
celgene
clinical trials
deals
bristol-myers squibb
gene therapy
novartis
pfizer
ipo
What
bio
drug
fda
roundup
new
cancer
approved
gene
medical
medicines
news
roche
therapy
approval
big
biotech
blueprint
companies
drugs
genetic
group
hold
known
lack
latest
liver
medicine
pharmaceutical
regulatory
ret
today
treatments
acquire
address
adu
advances
africa
agreed
aiming
alzheimer’s
Language
unset
Current search:
genentech
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
3 years ago
FDA Official: New “Playbook” Needed for CMC Reviews of Gene Therapy Products
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@techcrunch.com
4 years ago
Only 2% of genomic material available for research comes from Africa, 54gene wants to change that
@xconomy.com
5 years ago
Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
ESMO ’18: Precision Meds, Breast, Lung, and More from the Cancer Front
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine